Key Takeaways

• Lycia is this week’s clearest active candidate: 14.7 million shares at a proposed $16–$18, with a tentative Friday October 23 debut.
• Its experimental treatments still require clinical proof; management’s projected funding runway is an estimate, not a profitability promise.
• Bitari’s calendar dates conflict, and its proposed offering leaves concentrated voting control. Starton’s date and terms also remain unconfirmed.
• IPOScoop reports Web3Labs postponed. No replacement date or completed offering was verified in the sources checked.

IPO Week Preview

October 21, 2026 | Week October 19–23, 2026

With staff and AI research assistance By Frank Whitaker and Stan Rosenberg

Research timestamp: 2026-10-21T10:35:31+00:00

Frank on the company behind the ticker

Lycia caught my attention because its experimental medicines aim to remove troublesome proteins, rather than merely block them. South San Francisco is its home; Carolyn Bertozzi's research helped establish the scientific approach, and Aetna Wun Trombley leads the company. Its pipeline lists early human studies for food allergy and Graves' disease. Those are potential markets, not established product sales. [4][6]

Stan on what the money buys

Lycia's October 20 filing proposes 14.7 million shares at $16–$18. The $17 midpoint implies $249.9 million gross and approximately $227.8 million after estimated expenses. It held $148.1 million in cash and marketable securities at June 30 and projects financing into the second half of 2029 after the offering. Proceeds and existing resources would advance its allergy and Graves’ programs. The estimate depends on assumptions; approval requires more funding. [3]

A funding runway is useful, but it does not prove a medicine works. The commercial questions are whether trials show meaningful patient benefits, whether manufacturing scales, and whether a treatment can compete with existing care. Comparing an early research business with a profitable drugmaker would obscure those differences. Final price and a fully diluted valuation remain questions for the final documents.

Frank on the less settled entries

Bitari's name suggests computing, but readers should examine the operating business before the label. The Texas company hosts and maintains Bitcoin-mining equipment. Its amendment proposes 4,285,715 shares at $7, approximately $30 million gross. AI Power X would retain 85.87% voting control after the base offering, and 40% of net proceeds is earmarked for acquisitions and investments without an identified target. New shareholders would accept concentrated control and discretion over expansion spending. [8]

Its date remains unsettled: IPOScoop places it this week; Webull shows November 5. Neither calendar establishes a completed sale. [1][13]

Web3Labs, a Hong Kong business serving blockchain companies, is postponed according to IPOScoop, although Webull still shows October 22. Its previous terms are proposals, not a completed offering; no replacement date was verified. [5][13]

Starton develops continuous-delivery technology for cancer treatments. Webull shows October 23 and five million shares at $6; IPOScoop shows a date still to be announced and 6.7 million shares at $5–$7. That discrepancy deserves a place in the calendar, rather than a confident forecast. [11][12]

Dates and unanswered questions

Friday, October 23 remains Lycia's tentative first-trade date on IPOScoop. Renaissance independently includes the deal this week, but its public calendar masks the precise date. No final pricing date or trading time was verified. [1][2]

At the research cutoff, the company pages and filings checked yielded no additional specifically dated future investor meeting, earnings call, presentation or regulatory decision for Lycia or Bitari. This describes those sources; it does not imply the companies have no news. [3][6][7][8][10]

The useful next evidence is a final prospectus, company announcement or exchange notice. A proposed offering is still a proposal until the terms and event are confirmed.

Sources

[1] IPOScoop calendar: tentative dates and status. https://www.iposcoop.com/ipo-calendar/ [2] Renaissance calendar: independent weekly cross-check. https://www.renaissancecapital.com/IPO-Center/Calendar [3] Lycia SEC amendment October 20: terms, finances and funding. https://www.sec.gov/Archives/edgar/data/1806540/000162828026066381/lyciatherapeutics-sx1a.htm [4] Lycia overview: leadership and scientific approach. https://lyciatx.com/about/overview/ [5] IPOScoop Web3Labs: business, former terms and postponement. https://www.iposcoop.com/ipo/web3labs-global-of-hong-kong/ [6] Lycia pipeline: clinical stages and development plans. https://lyciatx.com/pipeline/programs/ [7] Lycia news: announcements and future-event check. https://lyciatx.com/news/ [8] Bitari SEC amendment October 14: terms, management and control. https://www.sec.gov/Archives/edgar/data/2091680/000118518526004746/bitaris1a3101326.htm [9] IPOScoop calendar repeat: status cross-check. https://www.iposcoop.com/ipo-calendar/ [10] Bitari official site: business and future-event check. https://bitari.ai/ [11] Webull Starton: unconfirmed October 23 timetable. https://www.webull.com/quote/nasdaq-sta [12] IPOScoop Starton: conflicting terms and TBA date. https://www.iposcoop.com/ipo/starton-holdings/ [13] Webull calendar: conflicting Bitari and Web3Labs dates. https://www.webullapp.com/quote/us/ipo?hl=en